Skip to main content

Table 2 Overall mean (SD) AKQoL, DLQI, EQ-5D-5 L, and EQ-VAS values and in subgroups of patients

From: Health related quality of life in patients with actinic keratosis – an observational study of patients treated in dermatology specialist care in Denmark

   AK-QoL DLQI EQ-5D-5 L EQ-VAS
   n Mean SD p-value n Mean SD p-value n Mean SD p-value n Mean SD p-value
Total population   286a 6.7 4.8   290b 1.99 2.71   276c 0.884 0.140   284 79.3 18.9  
Sex Men 137 5.3 3.7 <0.001 138 1.73 2.46 0.121 132 0.901 0.127 0.060 136 81.3 17.9 0.086
  Women 149 7.9 5.3   152 2.23 2.91   144 0.868 0.150   148 77.6 19.7  
Age groupsd <60 38 8.1 5.5 0.004 39 2.31 2.40 0.657 37 0.903 0.126 0.262 38 77.6 22.9 0.070
  60-69 103 6.6 4.7   102 2.27 3.36   98 0.895 0.134   102 81.9 16.7  
  70-79 86 7.3 4.7   87 1.75 2.38   84 0.888 0.139   85 81.1 18.1  
  ≥80 58 5.0 4.0   61 1.70 2.04   56 0.850 0.157   58 73.7 20.2  
Current AK Yes 252 6.5 4.9 0.018 257 2.13 2.83 0.009 244 0.881 0.140 0.229 252 79.0 19.3 0.553
  No 34 7.8 3.7   33 0.91 1.04   32 0.907 0.141   32 82.2 15.5  
Severe actinic damagee Yes 27 10.07 5.6 <0.001 27 4.59 4.07 <0.001 26 0.844 0.139 0.068 27 70.2 22.3 0.012
  No 259 6.30 4.5   263 1.73 2.38   250 0.888 0.147   257 80.3 18.3  
Suspected NMSCf Yes 38 6.0 5.2 0.259 39 2.64 4.07 0.950 37 0.856 0.160 0.343 39 71.8 22.6 0.030
  No 214 6.6 4.8   218 2.04 2.54   207 0.886 0.136   213 80.3 18.4  
Locationsf Face 178 6.5 4.7 0.640 182 2.11 2.68 0.531 170 0.884 0.133 0.784 179 79.4 19.0 0.671
  Non-facial 74 6.5 5.2   75 2.19 3.17   74 0.873 0.156   73 78.0 20.1  
Comorbiditiesf Yes 175 6.7 4.9 0.357 178 2.38 3.19 0.200 170 0.860 0.151 <0.001 175 74.9 20.1 <0.001
  No 77 6.1 4.7   79 1.57 1.64   74 0.930 0.097   77 88.1 13.4  
Current AK treatment Yes 125 7.0 5.6 0.402 127 2.43 3.38 0.186 120 0.900 0.130 0.221 123 78.2 20.3 0.609
  No 74 5.8 3.7   74 1.73 2.14   72 0.870 0.150   73 81.2 16.5  
Immunosuppressive treatmentf Yes 25 7.2 6.0 0.869 25 4.04 4.46 0.023 23 0.876 0.143 0.900 24 70.6 25.1 0.061
  No 227 6.4 4.7   232 1.93 2.52   221 0.881 0.140   226 80.1 18.3  
Previous SCC Yes 53 8.0 6.6 0.410 54 3.4 4.4 0.016 51 0.849 0.153 0.038 52 70.8 21.4 <0.001
  No 233 6.4 4.2   236 1.7 2.0   225 0.892 0.136   213 81.3 17.9  
  1. a26 incomplete questionnaires, b22 incomplete questionnaires, c36 incomplete questionnaires, dOne missing value, eSevere actinic damage defined as patients with multiple lesions, dominated by grade II-III AKs with moderate to severe field cancerization. fAnalysis of “Suspected NMSC”, “Locations”, “Comorbidities” and “Immunosuppressive treatment” only included patients who had current AK lesion/s at the study visit and who had answered the respective questionnaire